| | |

			membership | research programs | disease oriented working groups | related links American Society of Clinical Oncology May 31 - June 3, 2008 Paul Sondel Anti-Neuroblastoma (NB) Activity of Hu14.18-IL2 against Minimal Residual Disease in a COG Phase II Study Noelle LoConte Predictors of Dose Limiting Toxicities in Phase I Clinical Trials: The Impact of Age, Comorbidity, and Other Clinical and Non-Clinical Factors Cancer Immunology and Immunotherapy: Realizing the Promise NCI-sponsored symposium September 11-12, 2008 Paul Sondel Development of hu14.18-IL2 for GD2+ Tumors American Statistical Association - 2008 Joint Statistical Meetings August 2-7,2008 Jens Eickhoff A response adaptive design with pharmacogenomic biomarkers for targeted therapies Home | For Patients | Research | Shared Services | Funding | Education and Training | Outreach | About Us | Clinical Trials | Directions | Donations | Employment | Events | Find a Researcher | Newsroom | Site Map | Terms and Conditions Copyright 2007 Board of Regents of the University of Wisconsin System